DiaMedica Therapeutics Stock Target Price and Analyst Consensus
| DMAC Stock | USD 5.34 0.32 5.65% |
The current analyst and expert consensus on DiaMedica Therapeutics is Strong Buy, with 3 strong buy opinions. The current projected DiaMedica Therapeutics target price consensus is 8.33 with 4 analyst opinions. Check out Macroaxis Advice on DiaMedica Therapeutics to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.The most common way DiaMedica Therapeutics analysts use to provide recommendation to the public is financial statements analysis. Many experts also interview DiaMedica Therapeutics executives and customers to further validate their buy or sell advice. Please note, the number of analysts providing the opinion is not sufficient to provide adequate consensus on DiaMedica Therapeutics. We encourage you to use your own analysis of DiaMedica Therapeutics to validate this buy or sell advice. DiaMedica Therapeutics buy-or-sell recommendation module provides average expert sentiment on the projected DiaMedica Therapeutics target price to derive its highest and lowest estimates based on projected price volatility of 3.5168.
Lowest Forecast 7.58 | Highest Forecast 9.25 | Target Price 8.33 |
DiaMedica |
It's important to approach DiaMedica Therapeutics' target price projections with caution. While they can be useful as part of a broader investment strategy, they are inherently speculative and subject to various kinds of risk, including market volatility and unforeseen external factors. Always consider multiple aspects and do your own research when making investment decisions.
DiaMedica Therapeutics Target Price Consensus
DiaMedica target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. DiaMedica Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 4 | Strong Buy |
Most DiaMedica analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand DiaMedica stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of DiaMedica Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationDiaMedica Therapeutics Target Price Projection
DiaMedica Therapeutics' current and average target prices are 5.34 and 8.33, respectively. The current price of DiaMedica Therapeutics is the price at which DiaMedica Therapeutics is currently trading. On the other hand, DiaMedica Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
DiaMedica Therapeutics Market Quote on 2nd of December 2024
Target Price
Analyst Consensus On DiaMedica Therapeutics Target Price
DiaMedica Therapeutics Analyst Ratings
DiaMedica Therapeutics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about DiaMedica Therapeutics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of DiaMedica Therapeutics' financials, market performance, and future outlook by experienced professionals. DiaMedica Therapeutics' historical ratings below, therefore, can serve as a valuable tool for investors.Analyst Consensus Breakdown
Average Consensus Estimates
Analysts determine stock price targets through various methods, including financial modeling, peer comparison, and company analysis. The stock price target is the analyst's best estimate of the future price of a stock and is used by investors to make investment decisions. However, it is important to note that stock price targets are not guaranteed, and the actual price of a stock can differ significantly from the target due to various factors such as market conditions, economic events, and company developments.
Steps to utilize DiaMedica Therapeutics price targets
DiaMedica Therapeutics' stock target price is an estimate of its future price, usually made by analysts. Using DiaMedica Therapeutics' target price to determine if it is a suitable investment can be done through the following steps:- Look at DiaMedica Therapeutics' target prices provided by various analysts and compare them. This can help you gain a more balanced view of the Stock's potential.
- Look at the analyst's track record to determine if they have a history of accurately predicting stock prices.
- Look at the Company's financials, including revenue, earnings, and debt, to determine if it is in good financial health.
- Consider market conditions. For example, take into account the state of the economy, competition, and regulatory environment, to determine if DiaMedica Therapeutics' stock is likely to perform well.
- Diversify your portfolio and do not rely solely on stock target prices to make investment decisions. Invest in a mix of stocks, bonds, and other assets to manage risk.
Additional DiaMedica Therapeutics Value Projection Modules
Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of DiaMedica Therapeutics is a key component of DiaMedica Therapeutics valuation and have some predictive power on the future returns of a DiaMedica Therapeutics.Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Macroaxis Index Invested few shares | |
 | Online Gaming Invested few shares | |
 | Tech Growth Invested one share | |
 | Steel Works Etc Invested few shares | |
 | Size And Style ETFs Invested few shares | |
 | Disruptive Technologies Invested over 20 shares | |
 | Compulsion Invested one share | |
 | Momentum Invested few shares | |
 | Trump Equities Invested one share | |
 | Warren Buffett Holdings Invested few shares | |
 | Millennials Best Invested few shares | |
 | Automobiles and Trucks Invested over 200 shares |
Check out Macroaxis Advice on DiaMedica Therapeutics to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Please note, the presentation of DiaMedica Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, DiaMedica Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of DiaMedica Therapeutics' management manipulating its earnings.